Impact of HCV genetic differences on pathobiology of disease

Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

(2011) Paul J. Gaglio et al.   DIGESTIVE DISEASES AND SCIENCES

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

(2011) Jean-Michel Pawlotsky   HEPATOLOGY

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

(2011) Ching-Sheng Hsu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

(2010) C. M. Lange et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hepatitis C Prevalence in Patients With Hepatocellular Carcinoma Without Cirrhosis

(2010) Mohammad F. Madhoun et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

(2010) Fred Poordad et al.   HEPATOLOGY

Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-  in Huh-7 cells

(2010) V. Pazienza et al.   JOURNAL OF GENERAL VIROLOGY

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

(2010) Christian Markus Lange et al.   JOURNAL OF HEPATOLOGY

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation

(2010) Hui Li et al.   VIROLOGY

An antioxidant resveratrol significantly enhanced replication of hepatitis C virus

(2010) Mitsuyasu Nakamura   WORLD JOURNAL OF GASTROENTEROLOGY

Hepatoprotective effects of antioxidants in chronic hepatitis C

(2010) Ricardo Moreno-Otero   WORLD JOURNAL OF GASTROENTEROLOGY

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma

(2009) Zhongjie Hu et al.   CANCER SCIENCE

Mutations in the Hepatitis C Virus core Gene Are Associated with Advanced Liver Disease and Hepatocellular Carcinoma

(2009) S. L. Fishman et al.   CLINICAL CANCER RESEARCH

Development of hepatitis C virus vaccines: challenges and progress

(2009) Françoise Stoll-Keller et al.   Expert Review of Vaccines

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C

(2009) Salvatore Petta et al.   HEPATOLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

(2009) Savino Bruno et al.   HEPATOLOGY

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

(2009) Udayan Chatterji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection

(2009) Kazuhiko Koike   JOURNAL OF GASTROENTEROLOGY

Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: More questions than answers

(2009) Francesco Negro   JOURNAL OF HEPATOLOGY

90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT

(2009) P. Thompson et al.   JOURNAL OF HEPATOLOGY

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

(2009) I. Jacobson et al.   JOURNAL OF HEPATOLOGY

89 SAFETY, PLASMA PHARMACOKINETICS, AND ANTI-VIRAL ACTIVITY OF SCY-635 IN ADULT PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION

(2009) S. Hopkins et al.   JOURNAL OF HEPATOLOGY

8 POTENT HCV PROTEASE INHIBITORS WITH THE POTENTIAL FOR ONCE-DAILY DOSING AND BROAD GENOTYPE COVERAGE

(2009) L.J. Jiang et al.   JOURNAL OF HEPATOLOGY

10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

(2009) Y. Benhamou et al.   JOURNAL OF HEPATOLOGY

50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209

(2009) G.R. Foster et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis

(2009) Sara Raimondi et al.   JOURNAL OF HEPATOLOGY

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

(2009) Pierre-Yves Bochud et al.   JOURNAL OF HEPATOLOGY

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

(2009) Norio Akuta et al.   JOURNAL OF MEDICAL VIROLOGY

Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b

(2009) Mariko Kobayashi et al.   JOURNAL OF MEDICAL VIROLOGY

Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients

(2009) K. R. Reddy et al.   JOURNAL OF VIRAL HEPATITIS

Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms

(2009) F. J. Eng et al.   JOURNAL OF VIROLOGY

Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins

(2009) Valerio Pazienza et al.   LIVER INTERNATIONAL

Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C

(2009) Yoshihiko Tachi et al.   LIVER INTERNATIONAL

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice

(2009) Stéphane Chevaliez et al.   PLoS One

Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs

(2009) Jean-Michel Pawlotsky   Therapeutic Advances in Gastroenterology

Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4

(2008) J. F. ROSSIGNOL et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide

(2008) B. E. Korba et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis

(2008) Ming-Ling Chang et al.   BMC GENOMICS

Hepatitis C virus core protein downregulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b

(2008) Payal Arora et al.   CANCER LETTERS

Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors

(2008) Yuqiong Liang et al.   GASTROENTEROLOGY

Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis

(2008) Aurélie Piodi et al.   HEPATOLOGY

Occult hepatitis C: How convincing are the current data?

(2008) Martin-Walter Welker et al.   HEPATOLOGY

Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C

(2008) Ian Homer Y. Cua et al.   HEPATOLOGY

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Lipid droplets: a classic organelle with new outfits

(2008) Toyoshi Fujimoto et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin

(2008) Kathrin Overbeck et al.   JOURNAL OF HEPATOLOGY

Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation

(2008) Ravi Jhaveri et al.   JOURNAL OF INFECTIOUS DISEASES

Expert opinion on the treatment of patients with chronic hepatitis C

(2008) S. Zeuzem et al.   JOURNAL OF VIRAL HEPATITIS

Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis

(2007) Rami Moucari et al.   GASTROENTEROLOGY

Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C

(2007) Matteo Vidali et al.   JOURNAL OF HEPATOLOGY